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Abstract: Background: Pneumonia is one of the causes of morbidity and mortality in children and 
adults worldwide. WHO report in 1999 stated that the main cause of death due to infectious disease 
is pneumonia. The rising mortality rate among severe pneumonia patients is because they do not 
receive empirical antibiotic treatment according to the infecting pathogens. 
Objective: The purpose of this study is to identify the bacterial profile and the use of antibiotic 
treatment on pneumonia patients admitted to the pulmonology ward of Dr. Soetomo General Hospital 
in Surabaya, Indonesia. 
Methods: This descriptive observational study used the data from pneumonia patients admitted to the 
pulmonology ward of Dr. Soetomo General Hospital, Surabaya, from February to April 2018. The 
data was collected from the patients’ medical records, antibiotic use notes, and culture results of 
bacterial antibiotic sensitivity test. The total of antibiotic use was calculated using a defined daily 
dose (DDD) per 100 bed days. The quality of antibiotics was assessed using Gyssens method. The 
microbial mapping was acquired from a sputum culture test result. 
Results: The most prevalent bacteria in pneumonia patients were the Gram-negative bacteria and the 
most common species was Acinetobacter baumannii followed by Klebsiella pneumoniae. In contrast, 
the most common Gram-positive bacteria species was Streptococcus viridans. The total antibiotic use 
was 35.53 DDD/100 bed days, and ceftriaxone was the most commonly used antibiotic with 9.23 
DDD/100 bed days. Fifty percent of the antibiotic use was in category wise use of antibiotic. 
Conclusion: The Gram-negative bacteria were the most common cause of pneumonia and 
ceftriaxone was the most commonly used antibiotic for its cure. Fifty percent of the patients received 
ceftriaxone appropriately. 
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1. INTRODUCTION 
Pneumonia is one of the infectious diseases that still is 
prevalent in society, especially in developing countries. 
Pneumonia is one of the most common causes of morbidity 
and mortality among children and adults worldwide [1]. 
SEAMIC Health Statistics data in 2001 states that pneumonia 
is the third cause of death in Singapore and Vietnam and  
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places sixth in Indonesia and Thailand, seventh in Malaysia 
and ninth in Brunei [2]. In East Java, Indonesia, the 
prevalence of pneumonia in 2016 was 26.76% of the 
population [3]. Pneumonia patients in the pulmonology ward 
of Dr. Soetomo General Hospital were treated with 
antibiotic, to improve their condition and prevent the 
incidence of microbial resistance. However, the mortality 
rate is still sky-high, reaching 33% to 50%. 
Pneumonia patients are provided with antibiotic(s) and 
supportive treatment. Antibiotic treatment is given through 
microorganism data and sensitivity test result. However, the 
culture process requires time, therefore, empirical antibiotic 
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therapy is given to close the gap. The choice of empirical 
antibiotic is adjusted to the microbial sensitivity pattern in 
the ward. Empirical antibiotic is chosen from a wide 
spectrum group, to combat a wide range of pathogen 
possibilities. The uncontrolled usage of wide spectrum 
antibiotic treatment may cause unwanted outcomes such as 
the adverse effects of the drug or the likeliness of microbial 
resistance. Moreover, it may cause multiple problems, such 
as the incidence of superinfection, the soaring cost of 
medical treatment, more toxic adverse effects, and patients’ 
duration of stay [4]. 
In a multiple center study of antibiotic usage, 30% to 
80% of antibiotic usage is not in line with the indication [5]. 
In a study of pneumonia patients in Dr. Kariadi General 
Hospital in Semarang, Indonesia, microbial resistance 
occurred in several community-acquired pneumonia (CAP). 
The resistance occurred in 55% of Streptococcus pneumoniae 
towards oxacillin, and 100% in Staphylococcus haemolyticus 
towards cefotaxime. While in nosocomial pneumonia, 
bacterial resistance occurs in 100% of Acinetobacter 
baumannii towards amoxicillin with clavulanic acid [6].  
The usage of antibiotic in pneumonia treatment is not 
only a formality to complete the treatment but the usage 
needs to be controlled with highly intensive monitoring for 
excessive antibiotic usage which will increase the incidence 
of resistance. This phenomenon become a national and 
global focus. World Health Organization (WHO) has 
established Defined Daily Dosage (DDD) that then can 
compare the DDD per 100 bed days between time frame, 
another ward, another hospital, etc. and DU 90% as 
standardized methods in drug use study, and the advantage 
of the comparison in this study is to briefly illustrate the data 
[7]. WHO recognizes this method as an internationally 
applied standard in drug use study. 
All hospitals in Indonesia, including Dr. Soetomo General 
Hospital, are currently preparing antibiotic stewardship strategy 
through the formation of antibiotic resistance controlling 
program (ARCP) team, according to ministerial order of the 
Ministry of Health, no 8, 2015 [8]. The purpose of this study 
is to identify the antibiotic usage profile qualitatively and 
quantitatively based on the microbial characteristic of 
pneumonia patients in the pulmonology ward in Dr. Soetomo 
General Hospital. Moreover, the data is expected to be used 
as supplementing data in perfecting the antibiotic usage 
guidelines and supporting the development of ARCP in Dr. 
Soetomo General Hospital, Surabaya, Indonesia. 
2. MATERIAL AND METHODS 
This study was a descriptive observational study 
conducted at Dr. Soetomo General Hospital in Surabaya, 
Indonesia from February 2018 to April 2018. This study 
used the data of pneumonia patients admitted in 
pulmonology ward of Dr. Soetomo General Hospital in 
Surabaya. The data were taken using a purposive sampling 
technique based on the inclusion and exclusion criteria. The 
inclusion criteria of this study were patients age 18 years old 
and above, receiving antibiotic prescription but have not 
used the antibiotic before the culture. The exclusion criteria 
of this study were patients with other infections than 
pneumonia. The data used in this study were drawn from 
patients’ medical records, including the notes of antibiotic 
use, and culture results of bacterial antibiotic sensitivity test. 
The total use of antibiotic was calculated using DDD per 100 
bed days. The quality of antibiotic was assessed using 
Gyssens method [9]. The microbial pattern was acquired 
from sputum culture test result. 
2.1. Statistical Analysis 
Antibiotic usage profile was analyzed by summarizing 
the count of antibiotic use based on DDD per 100 bed days 
and Gyssens method. The data were analyzed using SPSS 
17.0.0 for Windows software, 2007, SPSS Inc. Chicago, IL, 
USA, and Microsoft Office 2013. 
2.2. Ethical Clearance 
This study followed the principles of the Declaration of 
Helsinki. This study had received ethical clearance from Dr. 
Soetomo General Hospital before the study begins (Ethical 
Clearance Number 0061/KEPL/II/2018). Details that might 
disclose the identity of the subjects under study were 
omitted. 
3. RESULTS 
3.1. Sample Characteristics 
A total of 153 pneumonia patients were admitted to the 
pulmonology ward of Dr. Soetomo General Hospital from 
February 2018 to April 2018. Based on the inclusion and 
exclusion criteria, 74 patients - comprising of 43 males 
(58.11%) and 31 females (41.89%) - were included in this 
study. Pneumonia mostly affected those older than 55 years 
old and the length of the stay (LoS) of the pneumonia 
patients was mostly between 7 and 14 days (Table 1).  
Table 1. Characteristics of subjects in the study. 
 N % 
Gender 
Male 
Female 
 
43 
31 
 
58.11 
41.89 
Age 
18-25 years old 
26-55 years old 
>55 years old 
 
1 
33 
40 
 
1.35 
44.59 
54.06 
Length of Stay 
<7 days 
7-14 days 
15-21 days 
>21 days 
 
16 
39 
12 
7 
 
21.62 
52.7 
16.22 
9.46 
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Table 2. Bacterial profile from sputum culture. 
Types of Bacteria  N % 
Gram-positive 
Streptococcus viridans 18 22.50 
Staphylococcus coagulase negative 7 8.75 
Staphylococcus aureus 3 3.75 
Gemella morbillorum 2 2.50 
Streptococcus sanguinis 1 1.25 
Gram-negative 
Acinetobacter baumannii 12 15 
Klebsiella pneumoniae 12 15 
Acinetobacter spp 3 3.75 
Enterobacter cloacae 3 3.75 
Pseudomonas aeruginosa 3 3.75 
Escherichia coli 2 2.5 
Enterobacter aerogenes 2 2.5 
Achromobacter species 1 1.25 
Aeromonas caviae 1 1.25 
Burkholderia cepacia complex 1 1.25 
Pseudomonas putida 1 1.25 
 
3.2. Bacterial Profile 
Based on the culture results of 74 patients, 17 species of 
bacteria were found, consisting of five Gram-positive and 
twelve Gram-negative bacteria. The frequently found Gram-
negative bacteria were Acinetobacter baumannii and Klebsiella 
pneumoniae. Whereas, the frequently found Gram-positive 
bacteria were Streptococcus viridans (Tables 2 and 6). 
3.3. Antibiotic Use 
As many as 13 types of antibiotics were given to the 
patients from February 2018 to April 2018. The total 
antibiotic use on pneumonia patients admitted to the 
pulmonology ward in Dr. Soetomo General Hospital from 
February 2018 to April 2018 was 35.53 DDD/100 bed days 
(21.09, 54.36, 31.15 respectively). Ceftriaxone was the most 
commonly used antibiotic with 9.23 DDD/100 bed days 
(Table 3). Twenty-two patients received combination 
antibiotic therapy with the most frequently given 
combination of ceftriaxone and levofloxacin (Table 4). The 
evaluation of antibiotic use qualitative using the Gyssens 
method showed that 50% of antibiotic usage was used 
rationally (Table 5). 
4. DISCUSSION 
Pneumonia is common in all age groups, but the 
mortality rate is 2 to 4 times higher in the age group of 60 
years old and above than in the age group of 50 years old. 
Pneumonia with its high mortality rate is widely known as 
the forgotten pandemic and transmitted through multiple 
pathways, such as coughing and sneezing [10]. In addition, 
no sufficient attention is given by medical professionals.  
The results of this study showed that the incidence of 
pneumonia was higher in males than in females. The finding 
of this study is in accordance with that from the previous 
study, where most patients were males [11]. The reason for 
this is that males are more exposed to greater tendencies of 
smoking and liquors, which are the CAP risk factors. 
Smoking habit in healthy adults can increase the risk of lung 
disease and become the etiology of bronchitis and 
pneumonia [10]. Other risk factors that can cause pneumonia 
are low socio-economic status, low nutritional status, low 
healthcare accessibility, unjust medical practices, and 
chronic disease sufferer [11]. 
In this study, pneumonia was found mostly in patients 
beyond 55 years old. In healthy normal adults, pneumonia is 
rare due to the defense mechanism of airway and lungs. Risk 
factors of incidence and mortality caused by pneumonia at 
later age are higher. Pahriyani (2015) states that the body 
immunity starts declining when someone reaches 50 years of 
age [12]. This is due to the change of anatomy and 
physiology of elderly due to the aging process, which 
tremendously affects the functional capacity of the lungs, 
such as the ability to deal with lung function deprivation, the 
increase in airway resistance towards infections, and the 
weakening of physical immunity. Farida (2017) reported that 
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Table 3. DDD/100 bed days calculation of antibiotics used. 
 N % DDD/100 Bed Days 
Ceftriaxone 1 g injection 49 63.64 9.23 
Levofloxacin 750 mg intravenous 46 59.74 15.22 
Cefixime 100 mg oral 21 27.27 0.88 
Ceftazidime 1 g injection 15 19.48 2.56 
Meropenem 1g injection 11 14.29 4.34 
Levofloxacin 500 mg oral 8 10.39 0.55 
Moxifloxacin 400 mg injection 4 5.19 0.55 
Cefoperazone Sulbactam 1 g injection 4 5.19 0.52 
Azithromycin 500 mg oral 3 3.9 0.31 
Gentamicin 80 mg injection 3 3.9 0.81 
Cefazolin 1 g injection 2 2.6 0.15 
Metronidazole 500 mg intravenous 2 2.6 0.30 
Ciprofloxacin 200 intravenous 1 1.3 0.01 
Clindamycin 300 mg oral 1 1.3 0.11 
Table 4. Antibiotics combination. 
 N % 
Ceftriaxone + Levofloxacin 11 50 
Meropenem + Levofloxacin 4 18.18 
Ceftazidime + Levofloxacin 3 13.64 
Ceftazidime + Moxifloxacin 2 9.09 
Cefoperazone Sulbactam + Levofloxacin 1 4.55 
Meropenem + Moxifloxacin 1 4.55 
Table 5. Gyssens method analysis results. 
Category Frequency % 
VI 
(No sufficient data) 
0 0 
V 
(No indication) 
0 0 
IV A 
(There is more effective alternative) 
0 0 
IV B 
(There is less toxic alternative) 
0 0 
IV C 
(There is less costly alternative) 
19 25.68 
(Table 5) contd… 
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Category Frequency % 
IV D 
(There is less broad spectrum alternative) 
0 0 
III A 
(Duration is too long) 
5 6.76 
III B 
(Duration is too short) 
13 17.57 
II A 
(Incorrect dose) 
0 0 
II B 
(Incorrect interval) 
0 0 
II C 
(Incorrect route) 
0 0 
I 
(Wise use of antibiotic) 
37 50 
 
Table 6. Antibiotic sensitivity test pattern. 
No. ATC Code  Antibiotics  Streptococcus viridans (+) N = 18 
Acinetobacter 
baumannii  
(-) N = 12 
Klebsiella 
pneumoniae  
(-) N = 12 
Acinetobacter spp  
(-) N = 3 
Enterobacter 
cloacae (-) N = 3 
Pseudomonas 
aeruginosa (-)  
N = 3 
Staphylococcus 
aureus (+) N = 3 
      n % n % n % n % n % n % n % 
1 J01DB04 Cefazolin - - - -  3/5 58% - - - - 1/3 33% - - 
2 J01DD01 Cefotaxime - -  1/2 50%  3/4 75% 1  100% 1  100% 1/3 33% 1/3 33% 
3 J01DD02 Ceftazidime 1/18 6%  1/4 25%  5/6 83% 1  100% 1  100% 1  100% - - 
4 J01DD04 Ceftriaxone 1/18 6%  3/7 42% 1/12 8% 1/3 33% - - - - 1/3 33% 
5 
J01DD62 
Cefoperazone 
Sulbactam 
 1/9 11%  3/4 75% 1/12 8% 1  100% 1  100% 2/3 67% 1/3 33% 
6 J01DH02 Meropenem - -  3/7 42% 1/12 8% 1  100% 1/3 33% 2/3 67% - - 
7 J01DH03 Ertapenem - - - -  1/6 17% - - 2/3 67% - - - - 
8 J01DH51 Imipenem - -  3/7 42%  1/4 25% 1  100% 1/3 33% 2/3 67% - - 
9 J01FA01 Erythromycin - - - - - - - - - - - - - - 
10 J01FF01 Clindamycin - - 0  0% - - - - - - - - 1/3 33% 
11 J01GB01 Tobramycin 1/18 6%  2/3 67%  3/4 75% - - 1  100% 2/3 67% 1/3 33% 
12 J01GB03 Gentamicin 1/18 6%  2/3 67%  3/4 75% 1  100% 1  100% 2/3 67% 1  100% 
13 J01GB06 Amikacin 1/18 6%  3/5 58%  5/6 83% 1  100% 1  100% 1  100% 1/3 33% 
14 J01MA02 Ciprofloxacin 1/18 6%  1/2 50%  3/4 75% 1  100% 1  100% 1  100% 1/3 33% 
15 J01MA12 Levofloxacin  4/9  44%  2/3 67% - - 1  100% 2/3 67% 1  100% - - 
16 J01MA14 Moxifloxacin - - - - 1/12 8% - - - - - - - - 
(-) Gram-Negative bacteria; (+) Gram-Positive bacteria 
 
elderly patients are more prone to pneumonia infection due 
to the disturbance of gag reflex, weakening of immunity, 
disruption of thermoregulation, and multiple degrees of 
cardiopulmonary abnormalities [11]. 
In this study, the most used antibiotic was intravenous 
ceftriaxone. A similar study by Anindia (2016) at Airlangga 
University Hospital showed that ceftriaxone was the most 
commonly used antibiotic [10]. Antibiotic choices available 
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for pneumonia patients are beta-lactam combined with 
intravenous anti-beta lactamase or the second and the third 
generation of intravenous cephalosporin, or intravenous 
respiratory fluoroquinolone. Mostly used antibiotic is 
ceftriaxone, which is the third generation cephalosporin with 
wide spectrum effectivity. Ceftriaxone has an advantage as 
compared to other cheaper third generation cephalosporins 
since there is no need for dose adjustment in patients with 
renal malfunction, longer half-life that enables once-daily 
dose, and least possibility of allergy. The mechanism of 
ceftriaxone inhibits bacterial cell wall synthesis by binding 
one or more of the penicillin-binding proteins (PBP) that 
inhibit the last step of transpeptidase to synthesize 
peptidoglycan on bacterial cell wall. Ceftriaxone is a broad-
spectrum antibiotic that is effective in dealing with most 
aerobic organisms, either Gram-positive or Gram-negative. 
Ceftriaxone is also more susceptible to Enterobacteriaceae, 
which is beta-lactamase producing strain. 
In this study, the most used antibiotic in pneumonia 
patients was the combination of ceftriaxone and 
levofloxacin. Based on the pneumonia guidelines, the 
combinations of antibiotics can be given to inpatients 
without modification factors since the combinations are 
intravenous beta-lactam altogether with anti-beta lactamase, 
or second and third generation of cephalosporin, or 
intravenous respiratory fluoroquinolone. Pneumonia patients 
with modification factor received the second and third 
generations of intravenous cephalosporin. Meanwhile, if 
atypical bacterial infection occurs, a new group of 
macrolides is administered. If there is no risk of 
pseudomonas infection, the third generation of cephalosporin 
can be combined with macrolide or fluoroquinolone.  
The culture of 74 patients showed 17 types of bacteria, 
consisting of five Gram-positive bacteria and twelve Gram-
negative bacteria. Based on the culture result, the most 
common causes of pneumonia were Streptococcus viridans 
found in 18 patients (22.5%), Acinetobacter baumannii in 12 
patients (15%), and Klebsiella pneumoniae in 12 patients 
(15%). The finding is different from the previous study 
which stated that the most common bacteria were 
Pseudomonas aeruginosa, Staphylococcus coagulase 
negative, and Streptococcus viridans [10]. It also differs 
from another study by Mudatsir (2012) conducted in Dr. 
Zainoel Abidin General Hospital in Banda Aceh, which 
stated that the most common bacteria were Klebsiella 
pneumoniae (38.6%), Pseudomonas aeruginosa (18.1%) and 
Acinetobacter spp (18.1%) [13]. Multicenter data from 
hospitals in Indonesia in 2012 showed that the most common 
cause of pneumonia from sputum analysis is Gram-negative 
bacteria, such as Klebsiella pneumoniae, Acinetobacter 
baumannii, and Pseudomonas aeruginosa, whereas Gram-
positive bacteria, like Streptococcus pneumoniae, 
Streptococcus viridans, Staphylococcus aureus are found 
only in small amount [2]. This culture result raises some 
concerns about a difficult therapy against Gram-negative 
bacteria, including bacterial resistance [14-17]. In addition, 
this result can affect the empirical antibiotic therapy 
regimens by where the antibiotics may become sensitive, 
intermediate, or resistant. However, according to the 
Ministry of Health of the Republic of Indonesia, empirical 
antibiotic therapy has to be prescribed based on the 
surveillance data of pathogen in local hospitals [18]. 
Based on the quality of antibiotic use concerning 
Gyssens method, 37 patients (50%) received antibiotics 
wisely. The knowledge regarding rationale of antibiotic 
therapy consists of two important evaluative aspects. The 
aspects include: first, quantity - the number of antibiotics 
given, and second, quality - the precision in choosing the 
type of antibiotics, dosage, and lengths of therapy. The 
quality of antibiotic therapy is assessed based on patients’ 
medical records. 
In IVC category, there are other cheaper types of 
antibiotics with the frequency of 19 (24.68%), such as the 
administration of intravenous levofloxacin administration of 
750 mg every 24 hours. The selected antibiotics for 
pneumonia are beta-lactam and anti-beta lactamase or the 
third generation of cephalosporin. Ceftriaxone is the cheaper 
version of the third generation of cephalosporin compared to 
levofloxacin which is a fluoroquinolone and according to 
Gyssens analysis is included in the IVC category. In IIIA 
category, there is an overuse of antibiotic with a frequency of 
6 (7.79%). Based on the data from IDSA/ATS/BTS, the use 
of antibiotics for pneumonia can range from 24 hours to 14 
days with the antibiotic sensitivity evaluation and patient 
clinical condition. The result of this study indicates that there 
are some antibiotics given in more than 14 days without 
evaluation of its effectivity. In IIIB category, too short the 
use of antibiotics with a frequency of 15 (19.48%) with mean 
of the use between 24 and 72 hours. This situation occurs 
when a patient is referred from another hospital, experiences 
complications of the secondary disease, or death. 
Antibiotic quality with a good score indicates the prudent 
use of an antibiotic. The administration is not only empirical 
but also definitive according to the bacterial antibiotic 
sensitivity testing. This result test needs to be accompanied 
with the recommendation of selected antibiotics after 
considering the clinical relevance of the patient. Microbial 
examination altogether with clinical conditions is important 
to perform surveillance, preventive and curative (treat 
infectious diseases), and control infections in hospitals, 
health care facilities, and community. 
CONCLUSION 
The microbial profile in pneumonia patients admitted to 
the pulmonology ward in Dr. Soetomo General Hospital was 
dominated with Gram-negative bacteria. The most common 
Gram-negative species was Acinetobacter baumannii, 
followed by Klebsiella pneumoniae. In contrast, the most 
common Gram-positive bacteria was Streptococcus viridans. 
The total of the antibiotics used was 35.53 DDD per 100 bed 
days, and the mostly used antibiotic was ceftriaxone with 
9.23 DDD per 100 bed days. Based on Gyssens method, half 
of the antibiotics used in pneumonia patients were 
appropriate. 
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